DLH has been invited to join the Biomedical Advanced Research and Development Authority’s (BARDA) Rapid Response Partnership Vehicle (RRPV)!
- RRPV accelerates medical countermeasures and technology development to address critical needs, including pandemic influenza, emerging infectious diseases, and other biological threats
- The consortium is composed of renowned technologists, innovators, industry, academia, and non-profit research institutions
Membership in this organization enables DLH to rapidly align with national priorities and emerging security needs.
- Allows for direct access to BARDA leadership and proactive engagement on critical biomedical and public health initiatives
- Fosters partnerships for innovation with other leading organizations within the RRPV
“This opportunity is already opening doors for DLH,” Jeanine Christian, President, Public Health & Scientific Research, says. “Customers know that DLH has the cutting-edge technology and scientific excellence required to enhance preparedness and rapid response for future public health emergencies.”
Why it matters: DLH has a legacy of supporting complex public health responses, large-scale clinical trials, and secure, scalable IT and data management platforms. Through advanced tools, real-time diagnostics, and proven expertise in clinical trial operations, DLH stands ready to help the RRPV rapidly translate scientific innovation into decisive, life-saving action for communities facing urgent public health threats.
